Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
This study is based on the hypothesis that terazosin, a blocker of alpha-1 receptors, will be effective in reducing excessive sweating caused by antidepressant treatment, and will have minimal adverse effects.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study of the Efficacy and Tolerability of Terazosin for the Treatment of Antidepressant-Induced Excessive Sweating|
- To study whether terazosin 1 to 5 mg/ day is effective in reducing antidepressant-induced sweating
- To determine if terazosin is tolerated and acceptable to patients as a potential treatment for antidepressant-induced sweating
- Determine the time-course of response, the dose-response relationship, and the magnitude of effect of treatment of antidepressant-induced sweating to assist in designing a subsequent double-blind, placebo-controlled study of this treatment.
|Study Start Date:||May 2005|
Sweating is a common and bothersome side effect of treatment with antidepressants. Most or all antidepressants have been clearly shown to cause excessive sweating. It is unclear to what extent excessive sweating caused by antidepressants becomes less or goes away with time. In many instances, it continues to be a problem even after 6 or more months on the antidepressant.
There is no generally accepted treatment for excessive sweating. This study has been designed to study whether terazosin is effective in reducing antidepressant-induced sweating, and whether it is well-tolerated and acceptable to patients. In addition, secondary objectives of this study are to determine the time taken for patients to respond to terazosin, the usual doses needed for improvement, and the extent of reduction in sweating. This information will not only help doctors in using terazosin for this purpose in their patients, but will help in designing further studies of this treatment.
|United States, Pennsylvania|
|Thomas Jefferson University Department of Psychiatry and Human Behavior|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||Rajnish Mago, MD||Thomas Jefferson University Department of Psychiatry and Human Behavior|